Predicting novel uses for approved drugs helps in reducing the costs of drug development and facilitates the development process. Most of previous methods focused on the multi-source data related to drugs and diseases to predict the candidate associations between drugs and diseases. There are multiple kinds of similarities between drugs, and these similarities reflect how similar two drugs are from the different views, whereas most of the previous methods failed to deeply integrate these similarities. In addition, the topology structures of the multiple drug-disease heterogeneous networks constructed by using the different kinds of drug similarities are not fully exploited. We therefore propose GFPred, a method based on a graph convolutional autoencoder and a fully-connected autoencoder with an attention mechanism, to predict drug-related diseases. GFPred integrates drug-disease associations, disease similarities, three kinds of drug similarities and attributes of the drug nodes. Three drug-disease heterogeneous networks are constructed based on the different kinds of drug similarities. We construct a graph convolutional autoencoder module, and integrate the attributes of the drug and disease nodes in each network to learn the topology representations of each drug node and disease node. As the different kinds of drug attributes contribute differently to the prediction of drug-disease associations, we construct an attribute-level attention mechanism. A fully-connected autoencoder module is established to learn the attribute representations of the drug and disease nodes. Finally, the original features of the drug-disease node pairs are also important auxiliary information for their association prediction. A combined strategy based on a convolutional neural network is proposed to fully integrate the topology representations, the attribute representations, and the original features of the drug-disease pairs. The ablation studies showed the contributions of data related to three types of drug attributes. Comparison with other methods confirmed that GFPred achieved better performance than several state-of-the-art prediction methods. In particular, case studies confirmed that GFPred is able to retrieve more actual drug-disease associations in the top k part of the prediction results. It is helpful for biologists to discover real associations by wet-lab experiments.

Identifying novel indications for approved drugs can accelerate drug development and reduce research costs. Most previous studies used shallow models for prioritizing the potential drug-related diseases and failed to deeply integrate the paths between drugs and diseases which may contain additional association information. A deep-learning-based method for predicting drug–disease associations by integrating useful information is needed. We proposed a novel method based on a convolutional neural network (CNN) and bidirectional long short-term memory (BiLSTM)—CBPred—for predicting drug-related diseases. Our method deeply integrates similarities and associations between drugs and diseases, and paths among drug-disease pairs. The CNN-based framework focuses on learning the original representation of a drug-disease pair from their similarities and associations. As the drug-disease association possibility also depends on the multiple paths between them, the BiLSTM-based framework mainly learns the path representation of the drug-disease pair. In addition, considering that different paths have discriminate contributions to the association prediction, an attention mechanism at path level is constructed. Our method, CBPred, showed better performance and retrieved more real associations in the front of the results, which is more important for biologists. Case studies further confirmed that CBPred can discover potential drug-disease associations.